On the other hand, a recent meta-analysis of 35 studies has shown that COVID-19 patients receiving anti-TNF treatment regardless of underlying diseases had a lower risk of hospitalization (OR 0.53; 95% CI 0.42-0.67) and ICU admission or death (pooled OR 0.63; 95% CI 0.41-0.96) (42). This evidence concerns the gene TNF and COVID-19.